These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 9861886)

  • 1. Once-daily drug for persons with HIV.
    Am Fam Physician; 1998 Dec; 58(9):2174-5. PubMed ID: 9861886
    [No Abstract]   [Full Text] [Related]  

  • 2. Once-daily nonnucleoside reverse-transcriptase inhibitor approved.
    Am J Health Syst Pharm; 1998 Dec; 55(23):2458. PubMed ID: 9853628
    [No Abstract]   [Full Text] [Related]  

  • 3. Experience with efavirenz in end-stage renal disease.
    Das S; Ghanem M; Huengsberg M
    Int J STD AIDS; 2004 Feb; 15(2):143. PubMed ID: 15006080
    [No Abstract]   [Full Text] [Related]  

  • 4. Efavirenz shows promising results.
    AIDS Patient Care STDS; 1998 Jan; 12(1):64-5. PubMed ID: 11361892
    [No Abstract]   [Full Text] [Related]  

  • 5. FDA approves once-daily efavirenz formulation, revised labeling.
    AIDS Treat News; 2002 Mar; (378):7. PubMed ID: 11965921
    [No Abstract]   [Full Text] [Related]  

  • 6. Antiretroviral therapy for previously untreated HIV-1-infected adults: 2NN, or just one?
    Carr A
    Lancet; 2004 Apr; 363(9417):1248-50. PubMed ID: 15094265
    [No Abstract]   [Full Text] [Related]  

  • 7. [Protease inhibitor sparing standard. Once daily efavirenz continues to be effective].
    MMW Fortschr Med; 2004 Apr; 146 Spec No 1():18-20. PubMed ID: 15373038
    [No Abstract]   [Full Text] [Related]  

  • 8. Sustiva added to three-drug combination.
    AIDS Patient Care STDS; 1998 Oct; 12(10):803. PubMed ID: 11362030
    [No Abstract]   [Full Text] [Related]  

  • 9. Intravenous drug users risk group should also benefit from simpler highly active antiretroviral therapy.
    Parienti JJ
    AIDS; 2002 Oct; 16(15):2097; author reply 2098. PubMed ID: 12370515
    [No Abstract]   [Full Text] [Related]  

  • 10. Efavirenz switches may be beneficial.
    AIDS Patient Care STDS; 2001 Sep; 15(9):496. PubMed ID: 11603362
    [No Abstract]   [Full Text] [Related]  

  • 11. First-line and second-line antiretroviral therapy.
    Kulwichit W
    Lancet; 2004 Jul 24-30; 364(9431):329-30; author reply 330. PubMed ID: 15276389
    [No Abstract]   [Full Text] [Related]  

  • 12. [HIV infection: DuPont Pharma presents the results of its antiretroviral agent].
    Allerg Immunol (Paris); 1998 Apr; 30(4):123-4. PubMed ID: 9631694
    [No Abstract]   [Full Text] [Related]  

  • 13. Once-daily dosing and the treatment of HIV disease.
    Laurence J
    AIDS Read; 2006 Sep; 16(9):444-5. PubMed ID: 17024761
    [No Abstract]   [Full Text] [Related]  

  • 14. [A "once daily" drug that with proven effectiveness. Efavirenz has successful outcome also in direct comparisons].
    MMW Fortschr Med; 2003 Apr; 145 Spec No 1():12-3. PubMed ID: 15011576
    [No Abstract]   [Full Text] [Related]  

  • 15. Can efavirenz be taken in the morning?
    Skeie L; Maeland A
    Scand J Infect Dis; 2006; 38(11-12):1089-91. PubMed ID: 17148083
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The steady-state pharmacokinetics of efavirenz and nevirapine when used in combination in human immunodeficiency virus type 1-infected persons.
    Veldkamp AI; Harris M; Montaner JS; Moyle G; Gazzard B; Youle M; Johnson M; Kwakkelstein MO; Carlier H; van Leeuwen R; Beijnen JH; Lange JM; Reiss P; Hoetelmans RM
    J Infect Dis; 2001 Jul; 184(1):37-42. PubMed ID: 11398107
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tricks of the trade in starting efavirenz therapy.
    LeFlore DB; DeSilva KE
    Am J Health Syst Pharm; 2000 Mar; 57(5):490-1. PubMed ID: 10711531
    [No Abstract]   [Full Text] [Related]  

  • 18. I want a new drug. An overview of three new anti-HIV drugs.
    Simmons P
    Res Initiat Treat Action; 1998 Jun; 4(3):9-11. PubMed ID: 11365539
    [TBL] [Abstract][Full Text] [Related]  

  • 19. First once-daily drug simplifies dosing, offers new options in HIV-1 treatment.
    AIDS Alert; 1998 Nov; 13(11):121-4. PubMed ID: 11365967
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Simplification therapy with once-daily emtricitabine, didanosine, and efavirenz in HIV-1-infected adults with viral suppression receiving a protease inhibitor-based regimen: a randomized trial.
    Molina JM; Journot V; Morand-Joubert L; Yéni P; Rozenbaum W; Rancinan C; Fournier S; Morlat P; Palmer P; Dupont B; Goujard C; Dellamonica P; Collin F; Poizot-Martin I; Chene G;
    J Infect Dis; 2005 Mar; 191(6):830-9. PubMed ID: 15717256
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.